Merck & Co., Inc. (NYSE:MRK) Releases Earnings Results, Beats Expectations By $0.40 EPS

Merck & Co., Inc. (NYSE:MRK) announced its quarterly earnings data on Thursday. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.09 by $0.40, FiscalAI reports. The business had revenue of $18.09 billion during the quarter, compared to analyst estimates of $17.33 billion. Merck & Co., Inc. had a return on equity of 16.56% and a net margin of 3.64%. The company’s revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.58 earnings per share.

Here are the key takeaways from Merck & Co., Inc.’s conference call:

• Third-quarter revenue rose 5% to $18.1 billion, while Merck raised the midpoint of its 2026 revenue and EPS guidance to $66.8–$67.3 billion and $2.77–$2.82, respectively.
• Newer products continued to gain traction, including WINREVAIR, whose sales increased 94% to $694 million, and WELIREG, up 58% to $307 million; KEYTRUDA sales also grew 6% to $8.6 billion.
• Management highlighted encouraging pipeline progress, including positive phase III data for sac-TMT in endometrial cancer, favorable results for the individualized cancer vaccine intismeran in melanoma, and positive phase IIb data for tulisokibart in hidradenitis suppurativa.
• Management expects more than $2 billion of 2027 revenue headwinds from generic competition and loss of exclusivity affecting BRIDION, the JANUVIA family, and A​​DEMPAS, while KEYTRUDA growth is expected to moderate ahead of its eventual loss-of-exclusivity period.
• Merck expects 2027 to be another investment year, with operating expenses rising at a mid- to high-single-digit rate as it funds launches and pipeline development; vaccine utilization trends, pricing pressure outside the U.S., and policy changes in Germany remain areas to monitor.

Merck & Co., Inc. Trading Up 2.3%

Shares of Merck & Co., Inc. stock traded up $3.42 on Friday, reaching $149.75. 12,341,136 shares of the company were exchanged, compared to its average volume of 10,161,115. The stock has a fifty day moving average price of $146.90 and a 200-day moving average price of $126.69. The firm has a market capitalization of $369.46 billion, a price-to-earnings ratio of 154.38, a price-to-earnings-growth ratio of 6.38 and a beta of 0.21. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a fifty-two week low of $82.01 and a fifty-two week high of $156.92.

Insiders Place Their Bets

In other Merck & Co., Inc. news, EVP David Williams sold 52,847 shares of the business’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the sale, the executive vice president owned 31,716 shares in the company, valued at approximately $4,084,069.32. The trade was a 62.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP David R. Maraldo sold 18,706 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the sale, the executive vice president directly owned 18,212 shares of the company’s stock, valued at $2,344,248.64. This represents a 50.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 228,238 shares of company stock worth $29,977,783 over the last three months. Company insiders own 0.17% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Leerink Partners boosted their price target on shares of Merck & Co., Inc. from $127.00 to $161.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 9th. Zacks Research lowered shares of Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a research report on Monday, October 19th. Wells Fargo & Company raised their price objective on shares of Merck & Co., Inc. from $150.00 to $170.00 and gave the company an “overweight” rating in a research report on Friday, September 4th. UBS Group lifted their price objective on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Finally, Cantor Fitzgerald boosted their target price on shares of Merck & Co., Inc. from $120.00 to $145.00 and gave the stock a “neutral” rating in a report on Thursday, October 8th. Seventeen equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $156.08.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Strong Q3 results and raised outlook: Merck reported adjusted earnings of $2.49 per share versus the $2.09 analyst consensus, while revenue rose 4.7% year over year to $18.09 billion, ahead of estimates. Management raised its 2026 sales and adjusted-profit outlook, providing the main catalyst for the stock’s advance. Merck tops quarterly estimates and hikes profit outlook
• Positive Sentiment: Growth beyond Keytruda: Keytruda, including the newer Qlex formulation, delivered stronger-than-expected sales, while WINREVAIR continued to expand rapidly. Newer product launches are helping offset losses from generic competition and support Merck’s growth outlook. Merck Q3 earnings call highlights pipeline progress and raised outlook
• Positive Sentiment: Pipeline progress: Positive Phase 3 endometrial-cancer data for Keytruda and sacituzumab tirumotecan, along with FDA priority review for the latter, strengthens confidence in Merck’s oncology pipeline and its ability to address future revenue pressure. Merck Phase 3 endometrial cancer data and FDA review
• Positive Sentiment: Supportive analyst action: Guggenheim raised its price target to $171 and maintained a buy rating, indicating additional potential upside based on the earnings and pipeline outlook.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.